What are the possible side effects
Weekly GLP-1 receptor agonists typically reach steady-state concentrations after 45 weeks of regular dosing
I Understand, and I am 21+
Changes in menstrual bleeding can signal other health conditions, including fibroids, ovulation issues, hypothyroidism, polyendocrine metabolic ovarian syndrome (formerly PCOS), endometriosis, pelvic inflammatory disease (PID), bleeding disorders, and endometrial cancer
If continuing GLP-1 therapy, you should have a stable dosing regimen and understand the implications for surgery
Early data suggests this combination produces weight loss competitive with retatrutide, approximately 20-25% at optimal doses